INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 38 filers reported holding INOZYME PHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,460,931 | -19.0% | 3,681,174 | +7.4% | 0.41% | -8.8% |
| Q2 2023 | $19,094,428 | +3.7% | 3,428,084 | +6.6% | 0.45% | +3.2% |
| Q1 2023 | $18,421,377 | +468.5% | 3,214,900 | +4.2% | 0.44% | +464.1% |
| Q4 2022 | $3,240,328 | -56.9% | 3,086,027 | +9.9% | 0.08% | -59.8% |
| Q3 2022 | $7,524,000 | -40.3% | 2,807,618 | +6.3% | 0.19% | -47.0% |
| Q2 2022 | $12,593,000 | +158.1% | 2,640,056 | +121.3% | 0.37% | +197.6% |
| Q1 2022 | $4,880,000 | -17.6% | 1,193,195 | +37.4% | 0.12% | -10.2% |
| Q4 2021 | $5,923,000 | -39.9% | 868,466 | +2.2% | 0.14% | -33.8% |
| Q3 2021 | $9,852,000 | -31.2% | 850,015 | +1.2% | 0.21% | -26.9% |
| Q2 2021 | $14,318,000 | -12.7% | 840,272 | +1.5% | 0.28% | -20.9% |
| Q1 2021 | $16,392,000 | -4.4% | 827,900 | -0.3% | 0.36% | -1.4% |
| Q4 2020 | $17,142,000 | -25.9% | 830,546 | -5.6% | 0.36% | -38.2% |
| Q3 2020 | $23,134,000 | – | 879,954 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |